2014
DOI: 10.2298/mpns1404078z
|View full text |Cite
|
Sign up to set email alerts
|

The effect of angiotensin converting enzyme inhibition on effective renal plasma flow in patients with diffuse renal parenchymal diseases and hypertension

Abstract: The application of angiotensin converting enzyme inhibitors in patients with diffuse renal parenchymal disease and in individuals with essential hypertension may result in significant hemodynamic changes in the kidney, accompanied by changes in effective renal plasma flow. The extent of the changes caused by angiotensin converting enzyme inhibitors depends on the preexisting functional status of the kidney.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…In the presence of CKD, it is generally prudent to exercise caution regarding hazardous co-prescriptions and dietary habits that predispose to drug-drug and drug-nutrient interactions [23,83]. Preexisting renal function and parenchymal kidney disease influence subsequent renal status following ACEI initiation [84]. Yet, data are lacking on predictors of rise in serum creatinine (SCr) and the course following ACEI use.…”
Section: Angiotensin-converting Enzyme Inhibitors and Angiotensin Recmentioning
confidence: 99%
“…In the presence of CKD, it is generally prudent to exercise caution regarding hazardous co-prescriptions and dietary habits that predispose to drug-drug and drug-nutrient interactions [23,83]. Preexisting renal function and parenchymal kidney disease influence subsequent renal status following ACEI initiation [84]. Yet, data are lacking on predictors of rise in serum creatinine (SCr) and the course following ACEI use.…”
Section: Angiotensin-converting Enzyme Inhibitors and Angiotensin Recmentioning
confidence: 99%
“…99m Tc‐MAG 3 replaced 123 I‐OIH as the radiopharmaceutical of choice for gamma camera imaging many years ago due to excellent imaging qualities, availability and low cost as well as the low radiation dose to the patient (Bubeck et al, 1990; Itoh, 2001; Rehling et al, 1995; Russell & Dubovsky, 1999; Russell et al, 1988). However, the possibility to perform accurate measurement of RPF remains highly relevant, as RPF decreases with kidney disease and may be altered secondary to administration of several pharmaceuticals (Itoh, 2001; Prowle et al, 2010; Zeravica et al, 2014). Measuring RPF using CIT is mostly reserved for research purposes whereas clinically, as for 99m Tc‐DTPA, 99m Tc‐MAG 3 has primarily been investigated with SIT (Rehling & Nielsen, 2000; Rehling et al, 1995; Russell & Dubovsky, 1999).…”
Section: Discussionmentioning
confidence: 99%